Concord Biotech's Valthera unit completes US FDA audit with one procedural observation

Concord Biotech's Valthera formulation facility in Gujarat underwent a US FDA audit that concluded successfully with only one minor procedural observation unrelated to GMP. The company does not expect any material impact on its current business operations or supplies.

This Wire brief sits within Fusion42's coverage of Biotech.